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Abstract 
The permeability transition pore (MTP) is a high conductance hannel of the mitochondrial inner membrane inhibited by cyclosporin 
A. While the physiological role of the MTP has not been clarified yet, it is becoming clear that this channel plays an important role in the 
pathways leading to cell death. The recent demonstrations that the MTP is controlled by the membrane potential, that a variety of 
physiological nd pathological effectors can modulate the threshold voltage at which pore opening occurs, and that surface potential may 
contribute to pore modulation provide a useful framework to describe the mechanistic aspects of pore function in isolated mitochondria. 
Here we (i) briefly review the key features of pore regulation, and report our recent progress on the role of oxidants and mitochondrial 
cyclophilin; and (ii) elaborate on how MTP regulation by cellular pathophysiological effectors (such as cytosolic [Ca 2.] transients, 
oxidative stress, and changes in the concentration of polyamines, nitric oxide, and metabolites of both the sphingomyelin and 
phospholipase A 2 pathways) might take place in vivo. Further definition of the MTP checkpoints should help in the design of specific 
modulators, and offers great promise for the development of new conceptual nd pharmacological tools aimed at therapeutic intervention 
in pathological conditions where pore opening is a critical event. 
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1. Introduction 
After accumulation of Ca 2+, isolated mitochondria eas- 
ily undergo a permeability increase (the 'permeability 
transition', PT) to solutes with molecular masses up to 
1500 Da through pores with an estimated diameter of 
about 3 nm [1]. This leads to collapse of the proton 
electrochemical gradient, and therefore to cessation of 
ATP synthesis [2]. The ensuing Ca 2+ release, osmotic 
swelling, and hydrolysis of any available ATP by the F~ F 0 
ATPase have historically linked this phenomenon to mito- 
chondrial dysfunction [3]. This partly explains why sub- 
stantial progress has been made towards an understanding 
of the role of the PT in cellular pathology (e.g., Refs. [4] 
Abbreviations: PT, permeability transition; MTP, mitochondrial per- 
meability transition pore; CSA, CSH, cyclosporin A and H, respectively; 
Cyp-M, mitochondrial cyclophilin. 
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and [5], and [6] for a review), while its physiological role 
remains elusive (but see Refs. [7] and [8]). 
Under prevailing in vitro conditions the pores display a 
lack of selectit,i~ for the permeating species, and the only 
apparent discrimination between solutes is their molecular 
size. In the past, this property has been implied to mean 
that the pathway for permeabilization lacked specificity, 
i.e. it was not mediated by a protein designed for a 
physiological function [3]. The electrophysiological identi- 
fication of mitochondrial channels [9], the discovery that 
CSA is a high-affinity inhibitor of the PT, and the recent 
definition of the key control points of this complex phe- 
nomenon have drastically changed this picture (see Ref. 
[10] for a review). The field has come to agree that the PT 
is mediated by opening of a specific pathway (the MTP, a 
regulated inner membrane channel), which coincides with 
the mitochondrial megachannel independently identified 
by electrophysiological studies [9]. The fully opened state 
of the channel in the high-conductance (1 nS) mode ap- 
pears to correspond to the unselective state of the MTP 
observed in isolated mitochondria in vitro and in intact 
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cells under pathological conditions, while the frequent 
subconductance states displayed in single-channel mea- 
surements [9] might correspond to a more solute-selective 
state stabilized by CSA which has been recently described 
in isolated mitochondria [11]. In vitro MTP opening is 
fully reversible [12]. After pore closure mitochondria repo- 
larize recovering their energy-linked functions, and under 
proper conditions they regain their initial volume by solute 
extrusion [13]. Pore reversibility and its tight control by 
both the membrane potential and by matrix pH link its 
operation to the basic events of energy conservation, and 
suggest a physiological function which may be related to 
Ca 2+ homeostasis [8]. These advances confirm the pio- 
neering studies of Hunter and Haworth, who were the first 
to identify the 'transitional' nature of the permeability 
increase, and to argue that opening of a proteinaceous pore 
was responsible for this phenomenon [14-16]. 
Here we report our current understanding of the mecha- 
nistic aspects of pore regulation, and elaborate on how it 
could be modulated by intracellular signals. Due to severe 
space constraints, with few exceptions we refer the reader 
to recent reviews for papers published before 1994 [3,6- 
10]. 
2. Mechanistic aspects of pore regulation 
2.2. Surface potential 
The recent proposal that the pore also senses changes of 
the surface potential may represent a substantial improve- 
ment in our understanding of how MTP responses are 
modulated by a variety of heterogeneous agents [10,11]. 
Amphipathic anions (like fatty acids) behave as pore acti- 
vators with an effect hat cannot be explained by depolar- 
ization [ll]; and conversely, polycations (like spermine, 
Ref. [18]), positively charged peptides [19] and amphi- 
pathic cations (like sphingosine and trifluoroperazine) in-
hibit pore opening, the latter acting independently of inhi- 
bition of phospholipase A 2 [11]. The available data are 
consistent with the view that a more positive surface 
potential favors pore closure, while a more negative sur- 
face potential favors its opening. This hypothesis also 
resolves the puzzling observation that atractylate and 
bongkrekate, both inhibitors of the adenine nucleotide 
translocase, affect he pore in opposite directions. Atracty- 
late, which stabilizes the translocase in the 'c' conforma- 
tion, favors pore opening while bongkrekate, which stabi- 
lizes the translocase in the 'm' conformation, favors pore 
closure. Since the 'm' to 'c' transition profoundly affects 
the surface potential in the expected irection, the effects 
of atractylate and bongkrekate on the MTP find an elegant 
explanation within the framework of pore modulation by 
the potential [ 11 ]. 
2.1. Membrane potential 
2.3. Matrix pH, CSA and MTP modulation by Cyp-M 
membrane interactions 
A useful description of many known pore responses to 
physiological and pathological signals can be made within 
the framework of its voltage-dependence, which was rec- 
ognized in 1992 [17]. The channel favors the closed state 
as the voltage becomes more negative inside, i.e. under 
physiological conditions. This appears to be an intrinsic 
property of the MTP which can be observed both in 
isolated mitochondria (by modulating the membrane poten- 
tial with uncouplers) and in patch-clamp experiments of 
single channels (by modulating the applied voltage) (see 
Refs. [10] and [9], respectively, for reviews). These find- 
ings led us to postulate the existence of a sensor which 
decodes the voltage changes into variations of the proba- 
bility of pore opening [10]. Irrespective of the molecular 
structure of the putative sensor, it appears that many 
effectors are able to modify the threshold voltage (the 
'gating potential') at which MTP opening occurs. Many 
pore agonists (for example oxidative agents) shift the 
apparent gating potential to more negative (physiological) 
values, thereby favoring pore opening, while many pore 
antagonists (like reducing agents) have the opposite ffect 
and favor its closure [10]. Thus, pore opening can be 
obtained by either depolarization, or by changing the 
threshold potential at which opening occurs. 
The MTP is potently inhibited by H + [14]. The effect of 
H + is exerted from the matrix side of the inner membrane, 
and is linked to reversible protonation of histidyl residues 
[20]. The pore is extremely sensitive to variations of matrix 
pH, in that at pH below about 7.0 the pore is substantially 
inhibited while at pH 6.5 it does not open even in fully 
depolarized mitocbondria [18]. The pore is also inhibited 
by nanomolar concentrations of CSA, and this effect is 
most likely mediated by Cyp-M, a member of the cy- 
clophilin family of peptidyl-prolyl-cis-trans-isomerases se- 
lectively localized to the mitochondrial matrix [21]. Based 
on recent findings, we propose that the inhibitory effect of 
both H + and CSA is due to unbinding of Cyp-M from the 
pore, which would result in increased probability of pore 
closure [22]. This hypothesis i supported by the findings 
that (i) Cyp-M can be released from submitochondrial 
particles by CSA or by H + but not by CSH, and the effect 
of acidic pH is prevented by diethylpyrocarbonate; this
matches MTP inhibition, which can be observed with CSA 
but not CSH, and with the relief of H + inhibition by 
diethylpyrocarbonate [20]; and (ii) that reaction of mito- 
chondria with phenylarsine oxide, a powerful pore agonist, 
increases the affinity of binding of Cyp-M to mitochon- 
drial membranes [23]. Thus, many agonists and antagonists 
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might modulate the MTP by affecting its interactions with 
Cyp-M. 
2.4. Pore modulation by redox agents at two separate sites 
Oxidative stress has long been known to increase the 
probability of pore opening, but the precise mechanism 
remains obscure [9]. In general, MTP opening is favored 
by oxidants of both pyridine nucleotides (like acetoacetate 
and oxaloacetate), glutathione (like tert-butylhydropero- 
xide), and of dithiols (like diamide), as well as by dithiol 
crosslinkers (like phenylarsine oxide and arsenite). Since 
pyridine nucleotides and glutathione levels are connected 
through transhydrogenase nd glutathione reductase, it was 
not clear whether these oxidative vents could be linked by 
a common mechanism [9]. After pointing out the impor- 
tance of dithiol-disulfide interconversion in the modulation 
of the MTP response to depolarization [24,25], quite re- 
cently we have been able to readdress this long-standing 
issue by independently modulating the levels of reduced 
pyridine nucleotides and glutathione in both energized [26] 
and deenergized [27] mitochondria. The results of our 
studies indicate that two sites can be experimentally distin- 
guished, both contributing to MTP modulation by oxidat- 
ing and reducing agents. 
(i) A first site (which we call the 'S-site') coincides 
with the oxidation-reduction sensitive dithiol [25]. Cross- 
linking of the S-site by arsenite or phenylarsine oxide, or 
its oxidation by oxidized glutathione is matched by in- 
creased MTP open probability under conditions where the 
pyridine nucleotides pool is kept in the fully reduced state 
[26,27]. This site can be blocked by both N-ethylmalei- 
mide and monobromobimane, and the effects of cross-lin- 
king or oxidation can be fully reverted by reductants like 
dithiothreitol. As indicated in the schematic picture re- 
ported in Fig. l, glutathione appears to be the immediate 
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Fig. 1. Modulation of the MTP open probability at the S-site. The scheme 
illustrates how the MTP open probability is affected by the S-site, a 
critical dithiol. A lower open probability is associated with the reduced 
form, and can be stabilized by reaction with both N-ethylmaleimide 
(NEM) or monobromobimane (MBM). The dithiol can be reversibly 
oxidized by oxidized glutathione, and a higher open probability is associ- 
ated with the disulfide. Finally, the dithiol can react with arsenite (or 
phenylarsine oxide, not shown). The cross-linked species is equivalent to 
the disulfide, and is matched by an increased open probability which can 
be reversed by dithiothreitol (DTT). The scheme is based on the experi- 
ments discussed in the text and described in detail in Refs. [26] and [27]. 
oxidant of the S-site, and many pore agonists (like organic 
hydroperoxides) affect it through changes in the levels of 
reduced glutathione rather than by direct oxidation [27]. 
(ii) A second site (which we call the 'P-site') is in 
apparent oxidation-reduction equilibrium with the pyridine 
nucleotides pool. Pyridine nucleotides oxidation is matched 
by increased MTP open probability under conditions where 
the glutathione pool is kept in the fully reduced state, or 
when the dithiol is reacted with arsenite. At variance from 
the S-site, this site cannot be blocked by monobromobi- 
mane or dithiothreitol, while it is sensitive to N-ethyl- 
maleimide [26]. Since the chemical reactivity of the S-site 
towards monobromobimane is unaffected when pyridine 
nucleotides are oxidized by a variety of treatments, we 
conclude that the two sites do not share common oxida- 
tion-reduction i termediates besides glutathione itself [27]. 
2.5. Two general mechanisms for MTP modulation ? 
From the identification of the above control points, a 
general picture emerges which may account for most 
known pore agonists and antagonists within the relatively 
simple framework of the MTP as a voltage-dependent 
channel activated by matrix Ca 2+ and modulated by Cyp-M 
membrane interactions. (i) Modulation by both the mem- 
brane and surface potential would be made possible by the 
voltage sensor, which is presumed to be located at the 
interface between the membrane and the outer aqueous 
phase [10]. This would render the pore responsive to 
changes of the proton motive force (for example, by 
inhibition of respiration or by uncoupling), to signalling 
molecules/events occurring in the cell (for example sphin- 
golipids and Ca 2 + transients) or resulting from metabolism 
of phospholipids on the mitochondrial membrane itself 
(such as fatty acids produced by phospholipase A 2 activa- 
tion), and to oxidative events through the P- and S-sites. 
(ii) Modulation by Cyp-M binding would be afforded by 
conformational changes effected by protonation or CSA, 
and would convey signals arising from the matrix. These 
signals may involve inner-outer membrane interactions at 
the contact sites [28], and possibly hitherto unsuspected 
biochemical signalling pathways. 
The idea that two classes of pore agonists can be 
distinguished - one acting through the sensor and one 
through Cyp-M - is supported by the finding that, depend- 
ing on the agonist, in long time-frame xperiments the 
MTP can be either fully sensitive to trifluoroperazine but 
not CSA, or fully sensitive to CSA but not trifluoropera- 
zine, and that with several agonists a long-lasting inhibi- 
tion can only be obtained when trifluoroperazine and CSA 
are added together, with a clear synergistic effect [11]. 
3. Pore modulation by cellular signals 
It is now clear that mitochondria play a major role in 
the regulation of intracellular Ca 2+ homeostasis [29-31], 
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and that they possess a mechanism which is kinetically 
competent for the efficient sequestration f Ca 2+ pulses in 
the submicromolar range [32]. It appears that Ca 2÷ sig- 
nalling to the pore is a feasible mechanism by which 
pathological conditions characterized by Ca 2÷ overload 
may cause mitochondrial dysfunction, such as the is- 
chemia-reperfusion syndrome (see, e.g., Refs. [33-35]). 
Potentiation of the Ca 2+ signal could be achieved by 
activation of phospholipase A2 through the production of 
free fatty acids, which may affect the pore open-closed 
transitions through changes of the mitochondrial surface 
potential [ 11 ]. 
Monovalent reduction of oxygen by the mitochondrial 
respiratory chain produces uperoxide anions, which then 
yield hydrogen peroxide through the superoxide dismutase 
reaction. The latter species oxidizes mitochondrial glu- 
tathione, and is therefore a likely candidate as an endoge- 
nous mediator which can affect MTP open-closed transi- 
tions at the S-site [36]. A similar mechanism can explain 
the cellular toxicity of organic hydroperoxides like tert- 
butylhydroperoxide [37] and of compounds undergoing 
redox cycling like menadione [24] and paraquat [38]. It is 
intriguing that depending on the dose a redox-cycling 
quinone can stimulate cell growth, trigger apoptosis, or 
cause cell necrosis through a mechanism which involves 
changes in the synthesis of polyamines and of cytosolic 
[Ca 2÷ ][39], and that cell killing by tumor necrosis factor 
involves overproduction of oxygen radicals by the mito- 
chondrial respiratory chain [40], and is mediated by sig- 
nalling through the sphingomyelin pathway which also 
yields mediators acting on the pore [10,11]. Finally, impor- 
tant synergistic effects have been observed between 
paraquat and nitric oxide [38], which may indirectly affect 
pore function through its reversible inhibition of cy- 
tochrome oxidase [41]. 
4. The pore and cell death 
Overwhelming evidence indicates that opening of the 
MTP is a key event in a variety of toxic, hypoxic and 
oxidative forms of cell injury [4-6,33-35,37], suggesting 
that pore dysregulation can be a final common pathway on 
which many noxius agents or conditions converge. The 
intriguing observation that the pore might also be involved 
in apoptosis [7] and the potential role of oxygen radicals as 
mediators of the death signal(s) in a variety of diseases of 
both genetic (like muscular dystrophy, Ref. [42]) and 
infectious nature (like AIDS, Ref. [43]) is rapidly extend- 
ing the interest on mitochondrial dysfunction in general, 
and on this channel in particular, to immunology, oncology 
and pathology. The definition of the mechanistic aspects of 
pore modulation [10], the demonstration that both glu- 
tathione and pyridine nucleotides oxidation affect he prob- 
ability of pore opening [26,27], and the identification of 
Cyp-M as a potential target for selective pore inhibition 
with non-immunosuppressive CSA derivatives [22] should 
lead to an improvement of our ability to control pore 
function in vivo, and offer great potential for pharmaco- 
logical treatment of diseases in which pore opening plays a 
role. 
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